Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Since 2000, the outlook for multiple myeloma has improved.

2.

Ineffective medication can remove the "worst fear" of schizophrenia.

3.

BMTs that are "half-matched" are effective in treating severe sickle cell disease.

4.

Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma

5.

According to a study, white Americans are overdiagnosing melanoma at an alarming rate.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot